Analysts’ Weekly Ratings Changes for Corvus Pharmaceuticals (CRVS)

Several analysts have recently updated their ratings and price targets for Corvus Pharmaceuticals (NASDAQ: CRVS):

• 1/29/2026 – Corvus Pharmaceuticals was given a new $30.00 price target on by analysts at Mizuho.
• 1/22/2026 – Corvus Pharmaceuticals had its price target raised by analysts at Jefferies Financial Group Inc. from $13.00 to $42.00. They now have a “buy” rating on the stock.
• 1/21/2026 – Corvus Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/21/2026 – Corvus Pharmaceuticals had its price target raised by analysts at Oppenheimer Holdings, Inc. from $15.00 to $32.00. They now have an “outperform” rating on the stock.
• 1/20/2026 – Corvus Pharmaceuticals had its price target raised by analysts at Barclays PLC from $16.00 to $28.00. They now have an “overweight” rating on the stock.
• 1/20/2026 – Corvus Pharmaceuticals was given a new $20.00 price target on by analysts at Mizuho.
• 1/20/2026 – Corvus Pharmaceuticals had its price target raised by analysts at HC Wainwright from $11.00 to $27.00. They now have a “buy” rating on the stock.
• 12/11/2025 – Corvus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.